The clinical benefit response in treatment of unresectable pancreatic carcinoma by endoscopic ultrasongraphy-guided interstitial implantation of iodine-125 seeds combined with gemcitabine chemotherapy

( views:307, downloads:0 )
Author:
JIANG Yue-ping()
JIN Zhen-dong(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
LI Zhao-shen(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
DU Yi-qi(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
LIU Yan(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
CHEN Jie(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
ZHAN Xian-bao(Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China)
Journal Title:
CHINESE JOURNAL OF PANCREATOLOGY
Issue:
Volume 8, Issue 05, 2008
DOI:
Key Word:
Pancreatic neoplasms;Endoscopic Ultrasonography;Brachytherapy;Iodine-125;Gemcitabine

Abstract: Objective To investigate the clinical benefit response (CBR) in treating the unresectable pancreatic carcinoma by applying the EUS guided iodine-125 seed implantation combined with chemotherapy of gemeitabine and comparing chemotherapy of gemcitabine alone. Methods Forty-one patients with unresectable pancreatic carcinoma were randomly divided into two groups, one group (Group A) included 21 cases which underwent EUS-guided iodine-125 seed implantation combined with gemcitabine chemotherapy, the rest 20 cases (Group B) were treated with gemcitabine chemotherapy alone. EUS-guided iodine-125 seed implantation were carried according to the treatment plan system (TPS), following chemotherapy after 1 week. Gemcitabine was administered at the dose of 1 000 mg/m2, through intravenous administration once a week for 3 consecutive weeks every 4 weeks. CBR was assessed. Results CBR of Group A was 57.1% and median time to CBR was 1 week and median duration of CBR was 21 weeks, while CBR of Group B was 25%, and median time to CBR was 4 weeks and median duration of CBR was 15 weeks (P<0.01). Conclusions EUS-guided iodine-125 seed implantation combined with chemotherapy of gemcitabine was superior to gemcitabine chemotherapy alone in the term of CBR in patients with unresectable pancreatic carcinoma.

  • [1]Peretz T,Nori D,Hilaris B,et al.Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation.Int J Radiat Oncol Biol Phys,1989,17:931-935.
  • [2]张福君,吴沛宏,赵明,等.CT导引下125I粒子植入治疗胰腺癌.中华医学杂志,2006,86:223-227.
  • [3]Van Hoff DD,Goodwin AL,Garoia L.Advances in the treatments of patient with pancreatic cancer:improvement in symptoms and survival time.The San Antonio Drug Development Team.Br J Cancer,1998,78(Suppl 3):9-11.
  • [4]Stephens CD.Gemcitabine:a new approach to treating pancreatic cancer.Onool Nuts Forum,1998,25:87-93.
  • [5]Carmichael J.Clinical response benefit in patients with advanced pancreatic cancer.Role of gemcitabine.Digestion,1997,58:503-507.
  • [6]Burris HA 3rd,Moore MJ,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial.J Clin Oncol,1997,15:2403-2413.
  • [7]NICE (National Institute for Clinical Excellence).Guidance on the use of gemcitabine for pancreatic cancer May 2001.
  • [8]Louver R,Labianea PH,Lledo G,et al.Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer:Results of a GERCOR and GISCAD Phase Ⅲ Trial.Journal of Clinical Oncology,2005,23:3509-3516.
  • [9]Sun S,Xu H,Xin J,et al.Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer:results of a pilot trial.Endoscopy,2006,38:399-403.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn